Français | Government of Canada BioPortal | |||||||||||
Home | Site Map | News Room | FAQ | Search | ||||||||
|
Home Publications Consultations 2001 Highlights of Montreal Roundtable IP/PHL
Montreal Session
April 25, 2001 Prepared by: Consultation Participants
Technical Resources Canadian Biotechnology Advisory Committee Canadian Biotechnology Secretariat Media Relations Facilitation Team Roundtable Consultation Purpose and ObjectivesThe Canadian Biotechnology Advisory Committee (CBAC) as part of its national consultation process held a roundtable in Montreal, Quebec, on April 25, 2001, to address matters concerning Biotechnological Intellectual Property and Patenting of Higher Life Forms. Roundtable PurposeTo engage stakeholders in a dialogue to provide advice to CBAC on possible policy initiatives regarding Biotechnological Intellectual Property and the Patenting of Higher Life Forms. Roundtable Objectives
Issues/Topics of DiscussionThe roundtable addressed three topics: identifying issues and guiding principles, the types of higher life forms, if any, that ought to be subject to patent protection; and determining Canada’s international role. The opinions presenting in this report should not be taken in any way as indicating a consensus among the participants. Topic 1: Identifying Issues and Guiding PrinciplesQuestion A: What are the key issues that need to be understood and assessed in determining Canada’s approach to developing a policy on IP and PHL?Social and Ethical Issues are ParamountParticipants in all groups stressed the importance of understanding and assessing the social and ethical issues related to biotechnology. The reasons for making social and ethical issues paramount is underscored when the following questions and statements are considered:
While participants had no specific answers to these questions, it was frequently mentioned that informed public debate was required to resolve them. These issues affect everybody, and should not be left to “the experts”. Some of the conditions identified for a constructive public debate on the ethics of biotechnology are as follows:
Should social and ethical issues be a part of the patenting process?There were three sets of views on the question as to whether social and ethical issues should be part of the patenting process. Some participants were of the view that as a property statute, the Patent Act is not the place to deal with social and ethical issues. A separate regulatory system should be in place. For example, a patent can be obtained for a new pharmaceutical, but it cannot be marketed without regulatory approval. If a separate regulatory system were to be devised, participants wanted more clarity in the relationship between patenting and the assessment of social and ethical concerns. Some felt that the system should combine flexibility with security so as to respect ethical considerations without slowing down scientific development. The overall benefit to society should be the guiding criteria. Other participants felt that moral considerations should take precedence over commercial ones in the patenting process. There was once a provision in the Patent Act that an illicit invention could not be patented. This kind of clause could be included in the Patent Act to deal with moral concerns. A number of participants felt that it was difficult to discuss patenting issues without a moral and ethical framework. Their reasoning was that once we decide what ends we want to achieve as a society, it would be much easier to determine the appropriate role of patenting. They suggested that CBAC should undertake consultations on social and ethical issues as soon as possible. The Pace of ChangeParticipants noted that the pace of change of biotechnology poses a particular challenge. Societal values also change. Whatever decisions are made will need to be reviewed and kept up to date as technology and values change. Public ConfidenceParticipants stated that the public is suspicious of industry and lacks confidence in the safety of biotechnology, particularly with respect to food. In this context, industry should err on the side of caution and work to gain consumer confidence. In response to public concerns, industry should set standards that are higher than government standards. In this way, the marketplace could serve as a kind of regulatory mechanism. On the other hand, the marketplace is also a driver of biotechnology, since biotechnological applications would not be developed if they could not be sold. Other IssuesOther issues that were raised include:
Canada’s patent protection policy will affect:
Question B: What are the principles that should be used to guide the development of a policy on IP and PHL?Participants were asked to comment on the principles on page 3 of the CBAC discussion paper as follows: Justice: Accountability: Autonomy: Beneficence: Respect for Diversity Knowledge Caution Participants had the following comments on the CBAC principles: Accountability and autonomy
Caution
Justice
Other Principles
Applying the Principles
Topic 2: What should be patentable?This topic addressed the questions of whether there should be a policy to permit patenting of higher life forms for particular purposes and, if so, what factors must be considered and what safeguards required? Patenting Plant MaterialsMost breakout group participants did not raise objections to patenting plants and their component parts, including proteins, genes and cells. Some participants agreed that the current definition of invention, which sets out some requirements for patentability, was sufficient (i.e. novelty, utility) and correctly interpreted in today’s law. For example, for a gene to be patented, it must be isolated, purified, and have a known function. The work and ingenuity required for these steps are, for some participants, sufficient for a gene to justifiably be considered an invention. Others expressed concern that the interpretation of novelty, utility and non-obviousness criteria for patents over genes was too simple a test to meet, and allowed mere discoveries of genes, as they exist in nature although isolated, to be patented. The mere ability to sequence genes should not enable people to obtain a monopoly through a patent. Something more, for example, modification of the gene, should be required. These participants felt that the current interpretation of the Patent Act definition of “invention” creates barriers to research because patented genes would be more costly and difficult to use. Investors are reluctant to fund research using patented genes for reasons of higher cost and less control. Participants supporting the current definition of invention and interpretation of the criteria for patentability felt that making the criteria more stringent would put Canada at a disadvantage vis-à-vis the rest of the world. Any disadvantage to patenting could generally be offset by the benefit of encouraging research through the information made available by the patent. Agreements for the use of patents can be made between the patent holder and those who want to use the patent for further research to overcome exclusivity imposed by patent. This discussion led to the observation that public policy needs to take into account the dependence of research on funding from the private sector. Investors require some assurances that they will receive compensation for research and development for their inventions. Public sector funding has been reduced, making it more difficult to undertake research for purely non-commercial ends. Government policy will need to take into account the distinction between research for commercial reasons and research solely for the benefit of humankind without commercial gain. A concern was expressed if it were possible to grant a patent for a single phenotype of an organism (an organism with particular characteristics) this would effectively give the patent holder a monopoly on the means to create the phenotype through a number of different processes or methods. This would inhibit others from finding other ways to create the same phenotype. This should not be allowed to occur. On the topic of plant breeder’s rights, participants agreed that Canada should amend its laws to conform to the 1991 UPOV. Some suggested that plant breeders’ rights are preferred over patenting of plants. Patenting Human and Animal MaterialParticipants began the discussion on patenting of human and animal material by exploring whether proteins should be patented. Proteins are chemicals. Some proteins are created by humans (i.e. they do not exist in nature). A patent on a protein does not place any restrictions on the end user or purchaser of these materials. Once the patented protein is purchased, the patent over the protein would not prevent the end user from using the protein as desired. The price imposed by the patent would be included in the cost the protein (as is the case for all patented inventions). In this light, there were no objections raised to patenting proteins with the exception of some participants who were concerned that this might decrease easy and inexpensive access to diagnostic testing. In the ensuing discussion on patenting genes, the group discussed the difference between discovery and invention in much the same terms as the group dealing with plant materials. The main concern expressed was with regard to the patenting of human genes and cells, which participants suggested should not be allowed because of its effect on the provision of health care. It was suggested that it might be necessary to have mechanisms or regulations outside the Patent Act to deal with issues that affect medical treatment. With regard to animal organs, participants wanted more information on the amount of intervention or modification that would be required for an organ to be patentable. Is a pig’s heart modified with anti-bodies patentable? How synthetic does an organ need to be to be considered patentable? With regard to human organs, it was noted that human organ donation legislation varies by province. Distinctions are made among various types of organs, e.g. skin, hair¸ as opposed to lungs, kidneys. It was noted that the real issue might not be patenting per se but the regulation of use. There is also a need to distinguish between patenting rights and proprietary rights over a patented object. The patenting of whole animals gave rise to considerable discussion. Participants expressed particular concern about the following:
Other participants felt that these issues were not insurmountable and that patenting of animals was simply an extension of current practice with respect to the ownership of animals. Animals are already treated as commodities in agriculture (i.e. bought and sold). How would patenting make a difference? Animal welfare issues can be dealt with within the patenting process. It would be necessary to make the patenting system more responsive to societal views and ensure transparency in the patenting process. One suggested approach was to create a mechanism or process by which to examine patents from a moral perspective, e.g., an ethical examination board. Other participants were concerned that this would become another barrier to obtaining a patent and that it would add time to the already long patenting process. Some participants felt that the patent system is an inappropriate too with which to deal with animal welfare issues. The purpose of patenting is to create wealth and keep Canada competitive. That objective should remain. With regard to the patenting of animal varieties, some participants felt that breeders’ rights would be preferable to patenting over animals because the latter is likely to be more expensive, possibly placing individual farmers at a disadvantage as compared to large agri-business. Inadequate protection by individuals could result, over time, in the loss of biodiversity. Further, the question of who owned traditional ecological knowledge needs to be addressed. It was noted that this was being discussed in current trade negotiations. Patentability of Processes Using Higher Life FormsThe participants chose to separate the question of patenting processes using higher life forms into two major considerations. First, they examined some principles that should guide all patenting of higher life forms. The main considerations are as follows:
In all of these considerations, the balance of benefits and risks of patenting processes using higher life forms needs to be evaluated. Furthermore, the moral issue of the rights of animals will need to be taken into account. Some participants felt that human therapies should be patentable since they automatically address the common good. Others thought otherwise, stating that the end does not justify the means. Topic 3: Canada’s International Roles and ObligationsThe third breakout discussion topic addressed Canada’s international obligations and role concerning biotechnological intellectual property and the patenting of higher life forms.
From the outset, it was recognized that Canada’s international obligations would reduce its ability to set its own policy. Indeed, some participants wondered what there was to discuss on this topic, since the international obligations were already decided. Others pointed out that there are some choices that Canada can make, and that in any case, a Canadian position taken on moral grounds should have precedence over international obligations. Still other participants believed that Canada should bring its patent law and patent system in line with that of the US for economic reasons. Moral, social and ethical issues should be addressed in other ways. A preference emerged for the European model, which seems more similar to Canadian expectations than the US model. It appears that this model, which reflects discussions among a number of countries, was able to identify and meld into its policy nuances that would be sought by Canadians. Among various criteria to be considered was that of not releasing genetically modified animals into the wild, and refraining from engineering changes in animals or human beings. Regarding the structuring of systems, an independent or parallel body to CIPO would be an interesting approach whereby it would be mandatory to revisit and review decisions periodically. This structure would also have to enable public participation. The context in which changes should take place should take into account the equitable sharing of benefits derived from biodiversity and the full array of international agreements, not only those pertaining to trade. Canada's industrial structure, that is small and medium-sized businesses, would allow us to be an important model for countries with a similar industrial structure. The length of time it takes to get a patent in Canada compared to other jurisdictions was of concern to some participants. This is one area where Canada’s performance must be comparable to that of its trading partners. A related issue was the length of time it takes for biotechnological products to get regulatory approval. This time could be shortened considerably if Canada adopted regulatory approval granted by countries with good regulatory processes, e.g., the US or the EU. One breakout group recommended that Canada look into implementing a patent restoration provision. This would allow patentees who have lost their period of exclusivity for the making, using or selling of their inventions, while meeting or awaiting regulatory approval, to make up for lost time. There seemed to be no reason not to have it. Two breakout groups noted that they preferred the European Union’s approach to experimental use exemption from patent infringement to be more relevant for Canada than the American approach, primarily because it allows more research to take place without fear of patent infringement. Please note that similar reports from each of the 5 CBAC roundtable consultations on Biotechnological Intellectual Property and the Patenting of Higher Life Forms, conducted across Canada from April 23 to May 4, 2001, will be posted on the CBAC website. As well, results from all 5 roundtables will be integrated into a single rollup report that will also be available on the CBAC website by the end of May 2001. Please visit the CBAC website at www.cbac-cccb.ca or call the CBAC toll-free number at 1-866-748-2222 for additional information or documents related to this or other CBAC projects. |
http://cbac-cccb.ca | ||||
Created: 2005-07-13 Updated: 2006-06-30 |
Top of Page |
Important Notices |